Details of the Drug

General Information of Drug (ID: DM6RVO4)

Drug Name

TransCon CNP

Synonyms

ACP-015

Indication

Disease Entry	ICD 11	Status	REF
Achondroplasia	LD24.00	Phase 2/3	[1]
------------------------------------------------------------------------------------

Cross-matching ID

References

1	ClinicalTrials.gov (NCT05598320) A Phase 2b, Multicenter, Double-Blind, Randomized, Placebo-controlled Trial Evaluating Efficacy and Safety of Subcutaneous Doses of TransCon CNP Administered Once Weekly for 52 Weeks in Children With Achondroplasia Followed by an Open Label Extension Period. U.S.National Institutes of Health.